CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis C$0.04 -0.01 (-11.11%) As of 10/10/2025 10:12 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesInsider TradesBuy This Stock About Kane Biotech Stock (CVE:KNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kane Biotech alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0552-Week RangeC$0.04▼C$0.14Volume8,475 shsAverage Volume81,303 shsMarket CapitalizationC$6.65 millionP/E RatioN/ADividend Yield3.08%Price TargetN/AConsensus RatingN/A Company Overview Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Read More Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNE Stock News HeadlinesKane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound CleanserSeptember 17, 2025 | finanznachrichten.deKane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound CleanserSeptember 16, 2025 | financialpost.comFRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many. | Stansberry Research (Ad)Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and SpraySeptember 10, 2025 | financialpost.comFKane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall ConferenceSeptember 4, 2025 | markets.businessinsider.comKane Biotech Inc.: Kane Biotech Announces Second Quarter 2025 Financial ResultsAugust 30, 2025 | finanznachrichten.deInsiders' CA$1.86m Investments In Red Following Kane Biotech's CA$825k Dip In Market ValueAugust 5, 2025 | finance.yahoo.comKane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care ConferencesJuly 31, 2025 | finance.yahoo.comSee More Headlines KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed this year? Kane Biotech's stock was trading at C$0.11 at the beginning of 2025. Since then, KNE shares have decreased by 63.6% and is now trading at C$0.04. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Kane Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$6.03 million Net Margins423.52% Pretax MarginN/A Return on Equity-94.49% Return on Assets-58.43% Debt Debt-to-Equity Ratio-331.42 Current Ratio0.80 Quick Ratio0.39 Sales & Book Value Annual SalesC$1.85 million Price / Sales3.60 Cash FlowC$0.00 per share Price / Cash Flow8.50 Book ValueC($0.01) per share Price / Book-7.77Miscellaneous Outstanding Shares166,233,000Free FloatN/AMarket CapC$6.65 million OptionableNot Optionable Beta0.03 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (CVE:KNE) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.